Author:
van den Ancker Willemijn,van Luijn Marvin M.,Ruben Jurjen M.,Westers Theresia M.,Bontkes Hetty J.,Ossenkoppele Gert J.,de Gruijl Tanja D.,van de Loosdrecht Arjan A.
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,Immunology,Immunology and Allergy
Reference51 articles.
1. Provan D, Singer CRJ, Baglin T, Lilleyman J (2004) Acute myeloblastic leukaemia (AML). In: Provan D, Singer CRJ, Baglin T, Lilleyman J (eds) Oxford handbook of clinical haematology, 2nd edn. Oxford University Press, Oxford, UK, pp 149–157
2. Chamuleau ME, Souwer Y, Van Ham SM et al (2004) Class II-associated invariant chain peptide expression on myeloid leukemic blasts predicts poor clinical outcome. Cancer Res 64:5546–5550
3. van Luijn MM, Chamuleau ME, Thompson JA et al (2010) Class II-associated invariant chain peptide down-modulation enhances the immunogenicity of myeloid leukemic blasts resulting in increased CD4+ T-cell responses. Haematologica 95:485–493
4. Banchereau J, Palucka AK (2005) Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 5:296–306
5. Ridgway D (2003) The first 1000 dendritic cell vaccines. Cancer Invest 21:873–886
Cited by
13 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献